Macitentan (Opsumit)


  • Pulmonary Hypertension (see Pulmonary Hypertension, [[Pulmonary Hypertension]])
    • RCT of Macitentan in Symptomatic Pulmonary Hypertension (2013) [MEDLINE]: macitentan improves morbidity and mortality in pulmonary hypertension (this is unique, as other agents in the treatment of pulmonary hypertension have not been demonstrated to have mortality benefits)



  • xxxx


  • PO

Dose Adjustment

  • Hepatic:
  • Renal:

Adverse Effects

Neurologic Adverse Effects

Hematologic Adverse Effects

  • Anemia (see Anemia, [[Anemia]])

Other Adverse Effects


  • Safety, tolerability, pharmacokinetics and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple dose study in healthy subjects. J Clin Pharmacol 2013;53(11):1131-1138 [MEDLINE]
  • Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917 [MEDLINE]